Canada Pension Plan Investment Board Boosts Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Canada Pension Plan Investment Board raised its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 20.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 167,100 shares of the medical equipment provider’s stock after buying an additional 28,300 shares during the period. Canada Pension Plan Investment Board’s holdings in Lantheus were worth $14,949,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Gabelli Funds LLC boosted its holdings in Lantheus by 1.2% during the 4th quarter. Gabelli Funds LLC now owns 58,500 shares of the medical equipment provider’s stock valued at $5,233,000 after acquiring an additional 700 shares during the period. Bridgewater Associates LP boosted its stake in shares of Lantheus by 55.7% during the fourth quarter. Bridgewater Associates LP now owns 109,678 shares of the medical equipment provider’s stock valued at $9,812,000 after purchasing an additional 39,216 shares during the period. Portolan Capital Management LLC grew its holdings in shares of Lantheus by 21.1% in the fourth quarter. Portolan Capital Management LLC now owns 812,630 shares of the medical equipment provider’s stock worth $72,698,000 after purchasing an additional 141,749 shares during the last quarter. CreativeOne Wealth LLC increased its stake in Lantheus by 38.9% in the 4th quarter. CreativeOne Wealth LLC now owns 7,175 shares of the medical equipment provider’s stock worth $642,000 after buying an additional 2,008 shares during the period. Finally, Synovus Financial Corp lifted its holdings in Lantheus by 13.4% during the 4th quarter. Synovus Financial Corp now owns 25,639 shares of the medical equipment provider’s stock valued at $2,294,000 after buying an additional 3,038 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on LNTH shares. Truist Financial upped their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. B. Riley dropped their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $129.43.

Insiders Place Their Bets

In related news, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 63,109 shares of company stock worth $6,016,046. Company insiders own 1.50% of the company’s stock.

Lantheus Trading Up 0.8 %

Shares of LNTH stock opened at $101.32 on Monday. Lantheus Holdings, Inc. has a twelve month low of $62.59 and a twelve month high of $126.89. The stock has a market cap of $6.94 billion, a P/E ratio of 16.86 and a beta of 0.20. The stock has a 50 day moving average of $95.39 and a 200 day moving average of $95.38.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million. On average, research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.